Infliximab
Anti-TNF monoclonal antibody
- Response rate
- Paradoxical worsening reported
- Onset
- —
- Route
- IV infusion
- Line
- Not recommended
- IgM effect
- N/A
Evidence summary
Anti-TNF monoclonal antibodies can paradoxically worsen TRAPS. Four patients developed acute flares within 12 hours of infliximab infusion. Unlike etanercept (soluble receptor mimetic), infliximab crosslinks membrane TNF and may activate TNFR1 signalling. Anti-TNF monoclonal antibodies (infliximab, adalimumab) are generally not recommended in TRAPS.